Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on X.com by @tomicki. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $188.66 as of June 1st. VEEV’s trailing and forward P/E were 34.68 and 21.28 respectively according to Yahoo Finance.
Veeva Systems Inc. (VEEV) is a structurally advantaged vertical SaaS company and the software backbone of the global life sciences industry, spanning CRM, clinical trial management, regulatory submissions, and quality systems. Its competitive advantage is anchored in deep domain specialization and FDA and EMA regulatory validation requirements, creating high switching costs that make systems irreplaceable once embedded in pharma operations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Unlike horizontal SaaS exposed to AI commoditization, Veeva benefits from compliance-driven workflows that cannot be replicated through generic code generation, reinforcing customer captivity. The separation from Salesforce strengthened autonomy, enabling full control over product roadmap, margins, and AI integration.
Adoption momentum in Vault CRM continues with over 115 live deployments and commitments from 9 of the top 20 global pharmaceutical companies, signaling enterprise penetration. Financially, Veeva combines ~75% gross margins, strong free cash flow, and a $6.46B net cash position, implying ~5x FCF ex-cash and a forward P/E near 18x versus a five-year median of 60x.
Management guides $3.6B FY2027 revenue and a $6B long-term run-rate by 2030, supported by a ~$20B+ TAM expanding toward $30–50B, indicating structural growth. While competition from Salesforce Life Sciences Cloud and biotech spending are risks, the regulated moat, expanding R&D suite beyond CRM, and strong balance sheet support resilience.
With the stock down ~50% from highs, the case centers on a high-quality compounder mispriced as a vulnerable SaaS name, where multiple normalization could drive rerating and upside as earnings, adoption, and margins continue compounding over a multi-year horizon, supported by strong cash generation visibility.
Previously, we covered a bullish thesis on Veeva Systems Inc. (VEEV) by Francesco Ferrari in March 2025, which highlighted its resilient vertical SaaS model in life sciences, high ARR, strong margins, and robust cash generation. VEEV’s stock price has depreciated by approximately 21.27% since our coverage. @tomicki shares a similar view but emphasizes AI-driven moat durability, CRM adoption momentum, and deeper valuation rerating potential.
Veeva Systems Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 62 hedge fund portfolios held VEEV at the end of the first quarter which was 75 in the previous quarter. While we acknowledge the risk and potential of VEEV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VEEV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
